Ensysce Biosciences (ENSCW) Interest Expenses (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Interest Expenses of -$992.0 for Q4 2025, down 152.05% year-over-year from $1906.0 in Q4 2024, and down 115.58% quarter-over-quarter from $6369.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Interest Expenses (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Interest Expenses data on file, last reported at -$992.0 in Q4 2025.
- Interest Expenses for Q4 2025 came in at -$992.0, down 152.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $12393.0 (down 99.03% YoY), and the FY2025 annual result was $12393.0, down 99.03% from the prior year.
- Interest Expenses fell to -$992.0 in Q4 2025 per ENSCW's latest filing, from $6369.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.2 million in Q1 2024 and troughed at -$992.0 in Q4 2025.
- A 5-year average of $158102.6 and a median of $7649.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses soared 83271.08% in 2024, then tumbled 152.05% in 2025.
- A 5-year view of Interest Expenses shows it stood at $12487.0 in 2021, then tumbled by 75.61% to $3045.0 in 2022, then surged by 11223.45% to $344799.0 in 2023, then plunged by 99.45% to $1906.0 in 2024, then plunged by 152.05% to -$992.0 in 2025.
- Business Quant data shows ENSCW's Interest Expenses at -$992.0 in Q4 2025, $6369.0 in Q3 2025, and $3160.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Ensysce Biosciences | - | - | - | -992.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -992.00 |
| Dec 31, 2025 | -992.00 |
| Sep 30, 2025 | 6,369.00 |
| Sep 30, 2025 | 6,369.00 |
| Jun 30, 2025 | 3,160.00 |
| Jun 30, 2025 | 3,160.00 |
| Mar 31, 2025 | 3,856.00 |
| Mar 31, 2025 | 3,856.00 |
| Dec 31, 2024 | 1,906.00 |
| Dec 31, 2024 | 1,906.00 |
| Sep 30, 2024 | 4,063.00 |
| Sep 30, 2024 | 4,063.00 |
| Jun 30, 2024 | 27,563.00 |
| Jun 30, 2024 | 27,563.00 |
| Mar 31, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 344,799.00 |
| Dec 31, 2023 | 344,799.00 |
| Sep 30, 2023 | 7,649.00 |
| Sep 30, 2023 | 7,649.00 |